20:29:00 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-11-21 Kvartalsrapport 2024-Q3
2024-08-22 Kvartalsrapport 2024-Q2
2024-05-23 Kvartalsrapport 2024-Q1
2024-03-22 Ordinarie utdelning CURAS 0.00 DKK
2024-03-21 Årsstämma 2024
2024-02-22 Bokslutskommuniké 2023
2023-11-23 Kvartalsrapport 2023-Q3
2023-08-24 Kvartalsrapport 2023-Q2
2023-05-25 Kvartalsrapport 2023-Q1
2023-03-31 Ordinarie utdelning CURAS 0.00 DKK
2023-03-30 Årsstämma 2023
2023-02-23 Bokslutskommuniké 2022
2022-11-24 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-24 Kvartalsrapport 2022-Q1
2022-04-27 Årsstämma 2022
2022-03-25 Ordinarie utdelning CURAS 0.00 DKK
2022-02-24 Bokslutskommuniké 2021
2021-11-25 Kvartalsrapport 2021-Q3
2021-08-24 Kvartalsrapport 2021-Q2
2021-06-01 Extra Bolagsstämma 2021
2021-05-20 Kvartalsrapport 2021-Q1
2021-03-26 Ordinarie utdelning CURAS 0.00 DKK
2021-03-25 Årsstämma 2021
2021-02-24 Bokslutskommuniké 2020
2020-11-30 Kvartalsrapport 2020-Q3

Beskrivning

LandDanmark
ListaSpotlight DK
SektorHälsovård
IndustriMedicinteknik
Curasight är verksamt inom läkemedelsbranschen. Bolaget är specialiserat inom utveckling av teknologiska produkter. Produktportföljen är bred och har sin huvudsakliga fokus på utveckling av produkter inom området Positron Emissions Tomography (PET). Verksamheten drivs med störst närvaro inom Skandinavien. Curasight har sitt huvudkontor i Köpenhamn.
2022-05-24 07:00:00

Curasight A/S ("Curasight" or "the Company" - TICKER: CURAS) hereby publishes the interim report for the period January 1 - March 31, 2022. The interim report is available as an attached file to this release and on the Company's website. Below is a summary of the report.

Curasight's CEO Ulrich Krasilnikoff comments:

"Curasight began the year by accomplishing several essential milestones and strengthening its position as a theranostic company. Among the highlights are the positive results from the investigator-initiated phase IIb studies regarding Neuroendocrine tumors (NET) and granting of our US patent application relating to uTRACE[©]. As we add more indications to our clinical development and update our strategy, we stand well-positioned to accelerate our position in cancer management - taking diagnostics and treatment to a new level."

January - March 2022
  • Net sales amounted to 0 (0) DKK
  • Operating profit/loss amounted to -777,877 (-376,093) DKK
  • Profit/loss before taxes amounted to -1,430,126 (-997,515) DKK
  • Profit/loss for the period amounted to -1,260,714 (-778,065) DKK
  • Total assets amounted to 100,069,057 (61,911,284) DKK
  • Equity ratio amounted to 97.8 (94.3)
  • Earnings per share amounted to -0.06 (-0.05)
Highlights during the first quarter
  • On January 10, Ulrich Krasilnikoff and Andreas Kjær were invited and attended J.P. Morgan 40th Healthcare Conference.
  • On January 18, Ulrich Krasilnikoff and Andreas Kjær presented the Company and its future plans, SEB Nordic Healthcare Seminar 2022.
  • On January 27, Curasight announced that results from an investigator-initiated phase II study performed by researchers at Rigshospitalet using the uTRACE® technology in neuroendocrine tumor patients demonstrate strong prognostic value and support of potential future use of uPAR-targeted radionuclide therapy in these cancers.
  • On February 10, Curasight announced that the Company had signed and completed an agreement to acquire the early-stage R&D company TRT Innovations ApS. Curasight intends to expand and accelerate its clinical programs and is strengthening the therapeutic platform.
  • On February 23, Curasight announced that the Company has expanded its clinical program with two additional indications - Neuroendocrine tumors (NET) and head and neck cancer.
Highlights after the period
  • On April 12, Curasight gave notice of the Annual General Meeting 2022 to be held on April 27, 2022, at the Company's premises.
  • On April 22, Curasight announced that the United States Patent and Trademark Office has granted Curasight's United States Patent Application no. 16/870,776 is ready for allowance and the patent will be issued with patent no. 1131137.
  • On April 25, Ulrich Krasilnikoff and Andreas Kjær were invited and attended Sedermeradagen Stockholm. The presentation is available on Sedermeras Youtube channel.
  • On April 27, Curasight held an Annual General Meeting. Resolutions with summarized decisions are available on the company's website.
  • On May 18, Ulrich Krasilnikoff and Andreas Kjær gave an update on the company's strategy at Kapital Partner's Life Science Seminar.